Abstract: The present disclosure relates to heat-treated Limosilactobacillus fermentum LM1020 for preventing hair loss and promoting hair growth, and more particularly, to heat-treated Limosilactobacillus fermentum LM1020 for preventing hair loss and promoting hair growth by promoting the proliferation of dermal papilla cells and a composition containing the same. Heat-treated Limosilactobacillus fermentum LM1020 of the present disclosure and a composition containing the same promotes the proliferation of dermal papilla cells, has excellent 5?-reductase-1 inhibitory activity, and promotes the expression of FGF7, FGF10, and EGF, which are growth factors, and thus have the effect of effect of preventing hair loss and promoting hair growth. The subject cell line referred to as Lactobacillus fermentum LM1020 has the International Depositary Authority accession number KCCM12918P, having been deposited on Dec. 23, 2020.

Abstract: The present disclosure relates to a strain of Lactobacillus gasseri LM1065 (KCCM13018P) and a composition of relieving premenstrual syndrome containing the strain. A strain of Lactobacillus gasseri LM1065 (KCCM13018P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO in blood and TL-6 gene expression and increasing the production ratio of prostaglandin E1/prostaglandin E2 in blood and DGLA levels. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions, and the like.

Abstract: The present disclosure relates to a strain of Lactobacillus reuteri LM1071 (KCCM12650P) and a composition for relieving menstrual pain, comprising the same. A strain of Lactobacillus reuteri LM1071 (KCCM12650P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO, prostaglandin E2 and leukotriene in blood and increasing epoxyeicosatrienoic acid (EET) and the production ratio of prostaglandin E1/prostaglandin E2. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions and the like.

Abstract: The present disclosure relates to Lactobacillus reuteri LM1071 (KCCM12650P) and a composition containing Lactobacillus reuteri LM1071 for improving the intestinal environment. Lactobacillus reuteri LM1071 (KCCM12650P) according to an embodiment of the present disclosure does not have hemolysis and biogenic amine production capability and has excellent biosafety and excellent intestine adhesion and thus can improve the intestinal environment and improve the intestinal health. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions, feed compositions, and the like.

Abstract: A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used to prevent and treat inflammatory diseases, and the LTA-derived glycolipid can be also used as the vaccine adjuvant.